Design: CCTG 594 is a controlled, unblinded, two-arm, randomized (1:1) clinical trial to evaluate the effectiveness of a clinic-based HIV ALERT specialist on improving endpoints of retention in care and maintenance of ART as compared to the current standard of care (SoC) in HIV primary care clinics.~Duration: Each subject will receive follow-up of at least 48 weeks.~Sample Size: A total of 300 subjects will be randomized, 150 per arm.~Study Population: Eligible subjects will include 1) newly diagnosed HIV-infected individuals entering primary HIV care at one of the CCTG clinics, or 2) previously diagnosed HIV-infected individuals who are out of care defined as having no visit with a prescribing HIV provider in the last 180 days and not on a stable ARV regimen.~Stratification: Subjects will be stratified based on study site and if they are newly diagnosed or returning to care.
CCTG 594 is a controlled, unblinded, two-arm, randomized (1:1) clinical trial to evaluate the effectiveness of a clinic-based HIV ALERT specialist on improving endpoints of retention in care and maintenance of ART as compared to the current standard of care (SoC) in HIV primary care clinics.